Quantitative Imaging Tools to Derive DW-MRI Oncological Biomarkers
Summary
Magnetic resonance imaging (MRI) is a diagnostic technique that takes pictures of organs of the body. It uses magnetic fields and radio waves that cannot be felt. This makes specific organs, blood vessels, or tumors easier to see. Diffusion MRI lets us measure the motion of water in the tumor. The purpose of this study is to see if new MRI methods can give us more information about the tumor.
Arms & interventions
- OtherMRI examinations
Patients will be imaged on a 1.5 T or 3 T MR scanner either from GE or Philips. Patients will receive a test-retest scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at main campus, will also be imaged weekly during their course of treatment.
- OtherMRI examinations
Patients will be imaged on a 1.5 T or 3T MR scanner within one week prior to treatment initiation and at two months and four months after treatment completion (+/- 1 week).
Outcome measures
Primary
For group 1: number of patients that have biomarkers that maybe early response to therapy indicators
The study is designed to determine if the MRI will provide quantitative imaging biomarkers to predict or assess early treatment response in R/M head and neck cancers. The MR data will be compared with clinical follow-up data. Additional sequence parameters.
Time frame: 1 year
For group 2: number of patients response to treatment
will be assessed using ROC curves with RECIST with the RECIST version 1.1 response as the gold standard and change in DW-MRI and image feature metrics as predictors.
Time frame: 1 year
Eligibility criteria
Study locations (1)
Memorial Sloan Kettering Cancer Center
New York, New York, 10065